China’s ongoing regulatory and policy reforms will have a profound game-changing impact on its drug development innovation eco-system. Furthermore, while China has struggled in the past to achieve reimbursement for innovative medicines, we are also beginning to see significant paradigm shifts in the market access landscape in China. However, despite being the second largest pharmaceutical market, the trade war between U.S. and China have injected unpredictability and uncertainty into the landscape, notably with the recent investment restrictions, as well as proposed export controls. Join us at the Key Regulatory and Policy Trends panel for insights from our experts.

2:00 to 2:15pm
China Summit Opening Remarks by
Joe Damond, Executive VP for International Affairs, BIO

2:15 to 3:15pm
Key Regulatory and Policy Trends in Biopharmaceutical Innovation

• Li Yan, Chief Medical Officer, Brii Biosciences

• Ye Li, Vice President of Government Affairs and Policy, Merck Biopharma China

• Jianqing Chang, Vice President, Drug Regulatory Policy, Tigermed

• Jeannette Chu, Managing Director, PricewaterhouseCooper

• Christian Davis, International Trae Partner, Akin Group

Moderator: Josh Berlin, Executive Director, BioCentury

Ability Level: All

Session ID: 563075